FDA
-
-
-
-
-
-
-
Agios licenses blood disorder drug from Oscotec for $25 million upfront
-
-
-
-
-
-
-
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
-
-
-
-
-
-
-
Truist Securities stays Buy on Agios Pharma (AGIO) as co seeks accelerated approval for mitapivat
-
-
-
-
-
-
-
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
-
-
-
-
-
-
-
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
-
-
-
-
-
-
-
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
FDA extends PYRUKYND review date to December for thalassemia treatment
-
326,460 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

